Published on
June 12, 2020

Headlines | June 12

Companies Mentioned
No items found.
People Mentioned


Market performance of featured publicly-listed psychedelic companies for the week of June 8th - 12th.


Champignon Brands ($SHRM | $SHRMF | $496)) announced the closing of its bought deal private placement for aggregate gross proceeds of $15,000,375. Press Release. The company selected Dalriada Drug Discovery to advance its IP portfolio (Press Release).

After market close, Champignon also released a corporate update, announcing name change, rebranding and planned spin out. Press Release

MindMed ($MMED | $MMEDF) announced that it is supporting and collaborating on a Phase 2 clinical trial evaluating LSD for the treatment of cluster headaches at University Hospital Basel's Liechti Lab. Press Release

Numinus ($NUMI | $LR23) received a Health Canada licence amendment to produce and extract psilocybin from mushrooms. Press Release

Mydecine Innovations Group ($MYCO | $NLBIF | $0NF) signed a partnership agreement with Applied Pharmaceutical Innovation, a translational commercial drug development institute hosted at the University of Alberta. Press Release

NeonMind Biosciences, a wholly-owned subsidiary of The Yield Growth Corp ($BOSS | $BOSQF | $YG3), announced that they have filed an additional provisional patent application related to the administration of psychedelics to treat compulsive eating disorder, obesity and related illnesses. Press Release

View All News


Robin Carhart-Harris published a highly-acclaimed opinion piece in The Guardian discussing the role psychedelic drugs can play in treating depression. Link

Health Europa published an article examining ibogaine as a long term solution to addiction. Link

Psychedelic Finance interviewed Ben Nikolaevsky, CEO of Pure Extracts Corp (Private). Link


View Spotlight Interviews

View Companies